The Prognostic Yield of Biomarkers Harvested in Chemotherapy-Naive stage II Colon Cancer: Can We Separate the Wheat from the Chaff?

Watson, Martin M.; Søreide, Kjetil

doi:10.2119/molmed.2016.00098

Cited by 2 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fourth, other factors that could affect the treatment outcome of stage II colon cancer were not included. Responses to chemotherapy or survival rate may be different according to MSI status, and socioeconomic status of individual may also affect treatment outcome [ 25 , 26 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data

Kim¹,

Won²,

Park³

et al. 2018

Cancer Res Treat

View full text Add to dashboard Cite

PurposeDebates exist regarding the effectiveness of adjuvant chemotherapy for stage II colon cancer. This study aimed to investigate the current status of adjuvant chemotherapy and its impact on survival for Korean stage II colon cancer patients by analyzing the National Quality Assessment data.Materials and MethodsA total of 7,880 patientswho underwent curative resection for stage II colon adenocarcinoma between January 2011 andDecember 2014 in Koreawere selected randomly as evaluation subjects for the quality assessment. The factors that influenced overall survival were identified. The high-risk group was defined as having at least one of the following: perforation/obstruction, lymph node harvest less than 12, lymphovascular/perineural invasion, positive resection margin, poor differentiation, or pathologic T4 stage.ResultsThe median follow-up period was 38 months (range, 1 to 63 months). Chemotherapy was a favorable prognostic factor for either the high- (hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.38 to 0.59; p < 0.001) or low-risk group (HR, 0.74; 95% CI, 0.61 to 0.89; p=0.002) in multivariate analysis. This was also the case in patients over 70 years of age. The hazard ratio was significantly increased as the number of involved risk factors was increased in patients who didn’t receive chemotherapy. Adding oxaliplatin showed no difference in survival (HR, 1.36; 95% CI, 0.91 to 2.03; p=0.132).ConclusionAdjuvant chemotherapy can be recommended for stage II colon cancer patients, but the addition of oxaliplatin to the regimen must be selective.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data

Kim¹,

Won²,

Park³

et al. 2018

Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Considering the high probability of disease recurrence following operation for patients with CRC and poor prognosis of this disease recurrence, it is significant to identify factors that can be used to predict the precise prognosis of such postoperative patients to determine appropriate postoperative adjuvant therapy and to decide on follow-up schedules. In recent years, there have been several studies shown that an increase number of molecular markers combined with conventional clinicopathological prognostic factors were used for predictive accuracy in patients with CRC [20][21][22].…”

Section: Discussionmentioning

confidence: 99%

Phosphorylated 4E-BP1 is associated with tumor progression and adverse prognosis in colorectal cancer

Chen¹,

Wang²,

Fan³

et al. 2017

neo

View full text Add to dashboard Cite

Phosphorylation of eukaryotic translation initiation factor 4E (eIF4E)- binding protein (4E-BP1) results in release of eIF4E, relieving translational repression and enhancing cancerigenic protein synthesis. This study aim to evaluate the level of phosphorylated 4E-BP1 (p-4E-BP1) in colorectal cancer (CRC) and to assess the cor-relation with clinicopathological factors and patient survival. The level of p-4E-BP1 was detected by immunohistochemistry and western bolt in patients with CRC. Then Cox regression model was used to evaluate the prognostic value of all covariates. Among 164 assessed patients, 95 (57.9%) patients showed high level of p-4E-BP1. We noted that the level of p-4E-BP1 was significantly associated with tumor differentiation, invasive depth, lymph node metastasis and TNM stage. Then we compared the mRNA and protein expressions of 4E-BP1 in tumor regions and paired adjacent normal colorectal mucosal tissues in CRC patients. mRNA and protein expressions of 4E-BP1 did not differ between colorectal cancer and corresponding normal tissues, while the phosphorylation level of 4E-BP1 was markedly increased in CRC. Survival analysis and Cox proportional hazards model revealed that p-4E-BP1 was an independent adverse prognostic factor for both overall survival (OS) (HR = 5.414, p = 0.029) and progression-free survival (PFS) (HR = 4.754, p = 0.042). Herein, our results indicate that high p-4E-BP1 level is associated with tumor progression and adverse prognosis. p-4E-BP1 might be a novel biomarker to predict the clinical outcome of patients with CRC.

show abstract

The Prognostic Yield of Biomarkers Harvested in Chemotherapy-Naive stage II Colon Cancer: Can We Separate the Wheat from the Chaff?

Cited by 2 publications

References 34 publications

Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data

Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data

Phosphorylated 4E-BP1 is associated with tumor progression and adverse prognosis in colorectal cancer

Contact Info

Product

Resources

About